Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Reuters NewMedia - Monday October 29, 2001
Robertson Stephens also said that it expects a loss of $1.28 per share for Gilead for 2001, narrower than the $1.30 per share loss it previously forecast. For 2002, the brokerage expects a loss of 68 cents a share, also narrower than the $1.11 per share loss it expected.
Gilead said on Oct. 26 it received approval from the U.S. Food and Drug Administration to use its drug Viread in the treatment of the HIV infection. Robertson said while approval was expected, it may allow for more broad use of the drug than it had foreseen. In early trade, Gilead was upo $2.37 to $70.04 in active dealings.
011029
RE011032
Copyright © 2001 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .